Bawei Chenxiang Powder Protects Cardiomyocytes from Myocardial Ischemia/Reperfusion Injury via the PI3K‐AKT Pathway

Background Ischemia‐reperfusion damage to cardiomyocytes is one of the main directions of cardiovascular disease research, and Bawei Chenxiang powder (BWCX) is a traditional ethnomedicinal compound preparation mainly used in the treatment of cardiovascular diseases. Based on serum pharmacology, the present study aimed to explore the potential mechanism of BWCX against myocardial ischemia‐reperfusion damage to cardiomyocytes. Materials and Methods We prepared BWCX‐serum containing. Using serum pharmacology and bioinformatics approaches, we explored its protective effects on H9C2 cells in a hypoxia/reoxygenation (H/R) model. Additionally, we investigated the underlying mechanisms. Results BWCX‐containing serum can increase the survival rate of H9C2 cells and reduce oxidative stress levels in a H/R model. Specifically, it decreases the release of MDA, LDH, CK, and ROS, while increasing the levels of CAT, SOD, GSH‐PX, and Complex I. Additionally, it downregulates the expression of NDUFA‐10, Trx, HO‐1, and Keap1, and upregulates the expression of Nrf2. These effects are potentially mediated through the PI3K‐AKT pathway. Conclusion In the present study, we found that BWCX powder exhibited significant ameliorative and reparative effects on H/R‐induced cardiomyocyte injury by alleviating the level of oxidative stress during hypoxia/reoxygenation and acting on the PI3K‐AKT pathway.